AIM ImmunoTech Inc (AIM)
0.403
+0.01
(+3.33%)
USD |
NYAM |
May 17, 16:00
0.409
+0.01
(+1.49%)
After-Hours: 20:00
AIM ImmunoTech Research and Development Expense (Annual): 10.94M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.94M |
| December 31, 2022 | 6.99M |
| December 31, 2021 | 7.672M |
| December 31, 2020 | 5.72M |
| December 31, 2019 | 4.651M |
| December 31, 2018 | 4.778M |
| December 31, 2017 | 4.098M |
| December 31, 2016 | 5.107M |
| December 31, 2015 | 8.038M |
| December 31, 2014 | 8.988M |
| December 31, 2013 | 8.36M |
| December 31, 2012 | 9.508M |
| December 31, 2011 | 6.722M |
| December 31, 2010 | 7.613M |
| Date | Value |
|---|---|
| December 31, 2009 | 6.995M |
| December 31, 2008 | 5.80M |
| December 31, 2007 | 10.44M |
| December 31, 2006 | 10.13M |
| December 31, 2005 | 5.218M |
| December 31, 2004 | 3.842M |
| December 31, 2003 | 3.15M |
| December 31, 2002 | 4.946M |
| December 31, 2001 | 5.78M |
| December 31, 2000 | 6.136M |
| December 31, 1999 | 4.737M |
| December 31, 1998 | 4.60M |
| December 31, 1997 | 3.20M |
| December 31, 1996 | 1.90M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.651M
Minimum
2019
10.94M
Maximum
2023
7.194M
Average
6.99M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.31M |
| Protalix BioTherapeutics Inc | 17.09M |
| Electromed Inc | 0.916M |
| Xtant Medical Holdings Inc | 1.336M |
| Armata Pharmaceuticals Inc | 33.77M |